arrow
C

Carole L. Wallis

stellenbosch university
H指数:36
被引数:4,245

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

人类免疫缺陷病毒感染者使用替诺福韦、拉米夫定和度鲁特韦启动或转换治疗时的病毒学及药物耐药性结局:一项前瞻性队列研究(在六个PEPFAR支持国家进行)

2025-11-260
PRE
A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa

一项横断面研究,评估在肯尼亚、津巴布韦、斯威士兰和南非开展的替诺福韦二吡呋酯为基础的暴露前预防项目中,被诊断为HIV-1感染者中HIV耐药突变的发生频率。

2025-08-200
OA
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

替诺福韦-拉米夫定-多替拉韦在初治和病毒学抑制个体中,从基于NNRTI的方案转换后的病毒学结局:一项13个中心的观察性分析

2025-07-011
OAAI
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With Human Immunodeficiency Virus From 6 Countries
2024-05-131
PRE
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
2023-05-152
OA
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study
2023-04-125
OA
Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis

参与者切换到二线抗逆转录病毒治疗易感病毒表现出较差的依从性和更差的结果: 观察性分析

2021-12-011
OA
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings
AIDS
IF3.1
2021-04-092
OA
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
2020-10-1621
OAAI
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings
2019-11-144
OAAI
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
2019-09-0127
OAAI
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial
2019-07-0114
PREAI